Notably, the FDA granted approval for the anti-PD-1 antibody pembrolizumab for thyroid cancer treatment in 2020, and clinical trials have substantiated the therapeutic efficacy of the anti-PD-1 antibody spartalizumab in locally advanced or metastatic ATC [11]. The gene discussed is PDCD1; the disease is thyroid gland carcinoma.